You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

FAMVIR Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Famvir patents expire, and when can generic versions of Famvir launch?

Famvir is a drug marketed by Novartis and is included in one NDA.

The generic ingredient in FAMVIR is famciclovir. There are eight drug master file entries for this compound. Ten suppliers are listed for this compound. Additional details are available on the famciclovir profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Famvir

A generic version of FAMVIR was approved as famciclovir by TEVA PHARMS on August 24th, 2007.

  Try a Trial

Drug patent expirations by year for FAMVIR
Recent Clinical Trials for FAMVIR

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
House Research InstitutePhase 3
House Clinic, Inc.Phase 3
NovartisPhase 2

See all FAMVIR clinical trials

Paragraph IV (Patent) Challenges for FAMVIR
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
FAMVIR Tablets famciclovir 125 mg, 250 mg and 500 mg 020363 1 2004-12-28

US Patents and Regulatory Information for FAMVIR

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Novartis FAMVIR famciclovir TABLET;ORAL 020363-003 Dec 11, 1995 DISCN Yes No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Novartis FAMVIR famciclovir TABLET;ORAL 020363-001 Apr 26, 1996 DISCN Yes No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Novartis FAMVIR famciclovir TABLET;ORAL 020363-002 Jun 29, 1994 DISCN Yes No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for FAMVIR

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Novartis FAMVIR famciclovir TABLET;ORAL 020363-002 Jun 29, 1994 ⤷  Try a Trial ⤷  Try a Trial
Novartis FAMVIR famciclovir TABLET;ORAL 020363-003 Dec 11, 1995 ⤷  Try a Trial ⤷  Try a Trial
Novartis FAMVIR famciclovir TABLET;ORAL 020363-001 Apr 26, 1996 ⤷  Try a Trial ⤷  Try a Trial
Novartis FAMVIR famciclovir TABLET;ORAL 020363-002 Jun 29, 1994 ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for FAMVIR

See the table below for patents covering FAMVIR around the world.

Country Patent Number Title Estimated Expiration
Czech Republic 283182 Guaninové deriváty, způsob jejich výroby a farmaceutické prostředky s jejich obsahem (GUANINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS IN WHICH SAID DERIVATIVES ARE COMPRISED) ⤷  Try a Trial
Spain 8602791 ⤷  Try a Trial
Denmark 167019 ⤷  Try a Trial
United Kingdom 9326177 ⤷  Try a Trial
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for FAMVIR

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0053902 96C0036 Belgium ⤷  Try a Trial PRODUCT NAME: FAMCICLOVIR; NAT. REGISTRATION NO/DATE: NL 21325 19960708; FIRST REGISTRATION: GB - 10592/0035 19931210
0182024 SPC/GB94/002 United Kingdom ⤷  Try a Trial SPC/GB94/002: 20050910, EXPIRES: 20081209
0141927 SPC/GB96/014 United Kingdom ⤷  Try a Trial SPC/GB96/014: 20040810, EXPIRES: 20090809
0141927 97C0033 Belgium ⤷  Try a Trial PRODUCT NAME: PENCICLOVIR; NAT. REGISTRATION NO/DATE: 981 IS 110 F 7; 19970206; FIRST REGISTRATION: GB 10592/0078 19960228
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.